MSD Germany has appointed Dr Susanne Fiedler as CEO to take over from Hanspeter Quodt, who steps after seven years in the post.
Dr Fielder first joined the German operations of Merck & Co in 1997, when she took up a role in market research.
She then moved to market, initially as a product manager and later as a marketing manager and then a business unit head with responsibility for a number of MSD products.
Since then Dr Fielder has served in the US, where MSD operates at Merck & Co, as global brand leader for the diabetes treatments Januvia and Janumet, before taking up a Sydney-based role as managing director of MSD Australia and New Zealand.
She will officially take on her new role on 1 February, when Quodt moves to a new European level position.
Source: PMLive
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.
